Pulmonx’s Leadership Shuffle Meets a $21.5M Q3: What LUNG Signals for Investors and Peers
By a seasoned finance writer who treats earnings disclosures like a chessboard—watchful of every move, and never euphoric about a single checkmate. Ticker: LUNG. In the pages that follow, we’ll touch on EPS, EPS consensus, earnings surprise, and revenue forecast as the narrative unfolds.
Executive snapshot: leadership and numbers in the near term
Pulmonx Corporation (Nasdaq: LUNG) released Exhibit 99.1 material alongside a press release detailing a management transition and preliminary third-quarter 2025 revenue. The company projects Q3 2025 worldwide revenue to be approximately $21.5 million, a figure described as preliminary and unaudited. In parallel, Glen French is reappointed President and Chief Executive Officer, with Derrick Sung taking on the roles of Chief Operating Officer and Chief Financial Officer, effective November 3, 2025. Concurrently, Steve Williamson and Mehul Joshi have resigned, though they will serve in advisory capacities through December 1, 2025 to facilitate a smooth transition. The formal earnings call and full-year outlook are slated for November 12, 2025, after the close of trading.
In the same breath, the release notes forward-looking statements and reiterates that no EPS figure or EPS consensus is provided in this initial release. Investors should anticipate that the upcoming earnings call will address EPS trajectory, potential earnings surprises, and the full revenue forecast for the remainder of 2025 and beyond.
What the numbers imply: the revenue signal and the missing pieces
The preliminary Q3 revenue target of about $21.5 million sets a baseline for the company’s near-term top line, but without disclosed EPS or a formal quarterly earnings figure, the market’s focus lands squarely on the path to profitability and the credibility of the updated revenue forecast for 2025. The absence of an EPS readout invites questions about margin progression, operating expenses, and any one-time costs tied to leadership reshuffle or strategic realignment. When the full results arrive, investors will be listening for whether the revenue pace translates into a meaningful EPS surprise or whether consensus expectations remain distant from the reality the new leadership aims to deliver.
Leadership transition: stability or signal?
The return of Glen French to the CEO role and the elevation of Derrick Sung to COO/CFO hints at a deliberate emphasis on operational discipline and financial stewardship. The timing—close to a quarterly print and a broader strategic reset—suggests management intends to re-anchor execution around a more tangible plan for monetizing the company’s interventional pulmonology platform. The resignations of Steve Williamson and Mehul Joshi, though couched as amicable and transitionary, will be scrutinized for any underlying governance signals or shifts in strategic priorities. In practice, this is a test of whether leadership changes can unlock stickier revenue growth and clearer margin outcomes without destabilizing ongoing programs.
Implications for peers and the sector
For sector peers, a well-executed leadership transition paired with a credible revenue narrative could underscore the value (and risk) of governance shifts in small-cap, specialized medical device companies. If the new leadership can translate the $21.5 million quarterly signal into a sustainable revenue trajectory and a path to EPS improvement, investors may reprice peers with similar product cycles, reimbursement dynamics, and market adoption challenges. On the flip side, any missteps in the near term—execution gaps, delays in product adoption, or unexpected cost overruns—could amplify scrutiny of smaller players facing long sales cycles and evolving regulatory landscapes.
Takeaways
Key actions for investors include watching the November 12, 2025 earnings call for updates to the Q3 results, the full-year outlook, and any change to the revenue forecast. Look for clues on EPS trajectory, possible earnings surprises, and the granularity of guidance across product lines and geographic markets. The leadership change may introduce near-term volatility in LUNG’s stock, but a coherent plan that demonstrates disciplined cost management and strategic growth could recalibrate expectations across the interventional pulmonology landscape and related sector peers.